产品
编 号：F762255
分子式：C15H25F3N4O5
分子量：398.38
分子式：C15H25F3N4O5
分子量：398.38
产品类型
规格
价格
是否有货
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 35240-69-8
产品详情
生物活性：
MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
体内研究：
MIF-1 TFA (Melanostatin, 1 mg/kg; i.p.; once, for 1 hour; male Wistar rats) modulates the analgesic effects, including stress-induced analgesia (SIA).MIF-1 TFA (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats.Animal Model:Male Wistar rats
Dosage:1 mg/kg
Administration:Intraperitoneal injection; once, for 1 hour
Result:Decreased the analgesic effect. Increased the pain threshold for at least 1 h.
Animal Model:Sprague-Dawley rats
Dosage:1 mg/kg
Administration:Intraperitoneal injection; daily, for 8 weeks
Result:Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol (HY-B1371) treatment.
体外研究：
MIF-1 TFA (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials.
MIF-1 TFA (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 TFA inhibits melanin formation. MIF-1 TFA blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 TFA accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
体内研究：
MIF-1 TFA (Melanostatin, 1 mg/kg; i.p.; once, for 1 hour; male Wistar rats) modulates the analgesic effects, including stress-induced analgesia (SIA).MIF-1 TFA (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats.Animal Model:Male Wistar rats
Dosage:1 mg/kg
Administration:Intraperitoneal injection; once, for 1 hour
Result:Decreased the analgesic effect. Increased the pain threshold for at least 1 h.
Animal Model:Sprague-Dawley rats
Dosage:1 mg/kg
Administration:Intraperitoneal injection; daily, for 8 weeks
Result:Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol (HY-B1371) treatment.
体外研究：
MIF-1 TFA (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备